Aspire Biopharma and PowerUp Team Up for Improved Drug Delivery
Transaction Highlights
- Valuation: Aspire Biopharma, Inc. is valued at around $316 million.
- Innovative Approach: The company is dedicated to advancing its product pipeline with cutting-edge delivery systems focused on FDA-approved drugs, nutraceuticals, and supplements.
- Cutting-edge Technology: Aspire’s proprietary delivery system facilitates rapid sublingual absorption of medications, reducing gastrointestinal side effects and enhancing safety.
- Anticipated Growth: The expected proceeds from this transaction will bolster Aspire's growth strategy and support the development of several critical therapeutic programs.
- Leadership Retention: CEO Kraig Higginson and the existing management team will continue to lead the company.
- Timeline: The business combination is projected to be finalized by late 2024 or early 2025.
As part of the upcoming business combination, Aspire Biopharma, Inc. and PowerUp Acquisition Corp. have signed a definitive merger agreement. This merger aims to combine Aspire’s innovative technology with PowerUp’s resources, creating a new leader in the biopharmaceutical industry. Once completed, the new entity is expected to operate as Aspire Biopharma Holdings, Inc. and will seek to list on Nasdaq under the symbol ASPIH.
Leadership Perspectives
Kraig Higginson, the CEO of Aspire, expressed enthusiasm about the future, emphasizing the chance to harness the strengths of both teams. This collaboration is set to introduce innovative, patent-pending products to the market and demonstrates Aspire's commitment to overcoming the limitations of traditional drug formulations.
Echoing this sentiment, PowerUp’s CEO, Suren Ajjarapu, highlighted their dedication to partnering with forward-thinking companies. Their shared vision for growth and innovation positions Aspire advantageously within the biopharmaceutical landscape.
About Aspire Biopharma
Based in Humacao, Puerto Rico, Aspire Biopharma is focused on transforming traditional drug delivery methods. Founded in 2021, the company aims to create solutions that improve patient safety, compliance, and efficacy for FDA-approved drugs, nutraceuticals, and supplements. Their unique approach includes a Novel Soluble Formulation designed to address urgent medical needs.
Instaprin: The Upcoming Launch
Among Aspire’s exciting developments is Instaprin™, a novel aspirin formulation engineered for rapid absorption, specifically targeting cardiac emergencies and pain relief. This innovative product seeks to tackle the challenges associated with conventional aspirin use, such as gastrointestinal issues. Aspire plans to submit a New Drug Application to the U.S. FDA for this effective formulation, utilizing a 505(b)(2) pathway to expedite the approval process.
Pipeline Innovations
In addition to Instaprin™, Aspire is actively working on a range of pharmaceutical and nutraceutical products, including a modern combination of Viagra and Cialis, hormonal treatments, and medications for traumatic brain injuries. This diverse pipeline underscores Aspire's commitment to advancing healthcare solutions.
Business Combination Details
The boards of both Aspire and PowerUp have approved the merger, which presents a significant opportunity to enhance Aspire’s product development and market presence. Proceeds from this merger are designated for accelerating Instaprin™ through regulatory processes, ensuring a swift market entry.
Following the merger, Aspire's shareholders will retain a substantial majority stake, reflecting strong investor confidence in the company’s future prospects.
Contact Information
Aspire Biopharma Contact:
TraDigital IR
Kevin McGrath
+1-646-418-7002
kevin@tradigitalir.com
PowerUp Acquisition Corp. Contact:
Suren Ajjarapu
Chief Executive Officer
347-313-8109
Suren@SRIRAMAAssociatesLLC.onmicrosoft.com
Frequently Asked Questions
What is the main goal of the Aspire and PowerUp merger?
The merger aims to leverage Aspire’s innovative drug delivery technology to enhance the efficacy of FDA-approved medications and improve patient outcomes.
What product is Aspire planning to launch?
Aspire is launching Instaprin™, a fast-acting aspirin formulation designed for quick absorption in medical emergencies.
When is the merger expected to be completed?
The business combination is anticipated to finalize by the end of Q4 2024 or early Q1 2025.
Who will lead the new combined company?
Kraig Higginson, the current CEO of Aspire, will retain his leadership role in the new entity.
How does Aspire's technology improve drug delivery?
Aspire's patented delivery technology enables rapid sublingual absorption, avoiding gastrointestinal effects and enhancing overall safety and efficacy.
